Company intelligence
American Society of Clinical Oncology (ASCO)
ASCO is committed to conquering cancer through research, education, and promotion of the highest quality care.
About American Society of Clinical Oncology (ASCO)
Founded in 1964, the American Society of Clinical Oncology (ASCO) is committed to making a world of difference in cancer care. As the world’s leading organization of its kind, ASCO represents more than 50,000 oncology professionals who care for people living with cancer. Through research, education, and promotion of the highest quality care, ASCO works to conquer cancer and create a world where cancer is prevented or cured, and every survivor is healthy. ASCO’s Conquer Cancer Foundation supports the Society by funding groundbreaking research and education across cancer’s full continuum. Learn more at www.ASCO.org. Use of our LinkedIn page is subject to our Social Media Policy (http://www.asco.org/about-asco/legal/social-media-policy) as well as applicable policies of LinkedIn
Verified activity
Signals from American Society of Clinical Oncology (ASCO)
5 published signals
Partnerships
American Society of Clinical Oncology (ASCO) collaborated with City Cancer Challenge (C/Can) for a Multidisciplinary Cancer Management Course in Concepción, Chile.
Reported by American Society of Clinical Oncology (ASCO)
Presence & Recognition
American Society of Clinical Oncology (ASCO) members Dr. Fumiko Ladd Chino, Chancellor Donald, M.D. & Christian Thomas spoke on the importance of federal cancer research funding.
Reported by American Society of Clinical Oncology (ASCO)
People
American Society of Clinical Oncology (ASCO) is seeking education innovators to join the 2027-28 ASCO LDP: Education Scholars program.
Reported by American Society of Clinical Oncology (ASCO)
Partnerships
American Society of Clinical Oncology (ASCO) is accepting proposals for the 2027-2029 International Palliative Care Education Collaboration.
Reported by American Society of Clinical Oncology (ASCO)
Presence & Recognition
American Society of Clinical Oncology (ASCO) presented data at ASCO 26 suggesting a RAS inhibitor nearly doubled survival for people with metastatic pancreatic cancer.
Reported by American Society of Clinical Oncology (ASCO)